Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorSubbiah, Vivek
dc.contributor.authorBraña Garcia, Irene
dc.contributor.authorLonghi, Alessandra
dc.contributor.authorBoni, Valentina
dc.contributor.authorDelord, Jean-Pierre
dc.contributor.authorAwada, Ahmad
dc.date.accessioned2022-09-09T07:38:05Z
dc.date.available2022-09-09T07:38:05Z
dc.date.issued2022-07-01
dc.identifier.citationSubbiah V, Braña I, Longhi A, Boni V, Delord JP, Awada A, et al. Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Relapsed Ewing Sarcoma: Results of a Basket Phase II StudyAntitumor activity of lurbinectedin in relapsed ES. Clin Cancer Res. 2022 Jul 1;28(13):2762–70.
dc.identifier.issn1557-3265
dc.identifier.urihttp://hdl.handle.net/11351/8089
dc.descriptionEwing Sarcoma; Lurbinectedin
dc.description.abstractPurpose: Lurbinectedin suppresses the oncogenic transcription factor EWS-FLI1 through relocalization to the nucleolus, and delays tumor growth in mice bearing Ewing sarcoma xenografts. On the basis of this rationale, lurbinectedin was evaluated in patients with relapsed Ewing sarcoma. Patients and Methods: This open-label, single-arm, Basket phase II trial included a cohort of 28 treated adult patients with confirmed Ewing sarcoma, measurable disease as per Response Evaluation Criteria In Solid Tumors (RECIST) v.1.1, Eastern Cooperative Oncology Group performance status ≤2, adequate organ function, no central nervous system metastasis, and pretreated with ≤2 chemotherapy lines for metastatic/recurrent disease. Patients received lurbinectedin 3.2 mg/m2 as a 1-hour infusion every 3 weeks. Primary endpoint was overall response rate (ORR) as per RECIST v.1.1. Secondary endpoints included time-to-event parameters and safety profile. Results: ORR was 14.3% [95% confidence interval (CI), 4.0%–32.7%], with median duration of response of 4.2 months (95% CI, 2.9–5.5 months). Median progression-free survival was 2.7 months (95% CI, 1.4–4.3 months), clinical benefit rate was 39.3%, and disease control rate was 57.1%. With 39% censoring, median overall survival was 12.0 months (95% CI, 8.5–18.5 months). Most common grade 3/4 adverse events were neutropenia (57%), anemia, thrombocytopenia, and treatment-related febrile neutropenia (14% each). No deaths or discontinuations were due to toxicity. Conclusions: Lurbinectedin was active in the treatment of relapsed Ewing sarcoma and had a manageable safety profile. Lurbinectedin could represent a valuable addition to therapies for Ewing sarcoma, and is currently being evaluated in combination with irinotecan in advanced Ewing sarcoma in a phase Ib/II trial.
dc.language.isoeng
dc.publisherAmerican Association for Cancer Research
dc.relation.ispartofseriesClinical Cancer Research;28(13)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectSarcoma d'Ewing - Tractament
dc.subjectOssos - Càncer - Tractament
dc.subjectOncogens
dc.subject.meshSarcoma, Ewing
dc.subject.mesh/drug therapy
dc.subject.meshBone Neoplasms
dc.subject.meshOncogenes
dc.titleAntitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1158/1078-0432.CCR-22-0696
dc.subject.decssarcoma de Ewing
dc.subject.decs/farmacoterapia
dc.subject.decsneoplasias óseas
dc.subject.decsoncogenes
dc.relation.publishversionhttps://doi.org/10.1158/1078-0432.CCR-22-0696
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Subbiah V] The University of Texas MD Anderson Cancer Center, Houston, Texas. [Braña I] Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Longhi A] Istituti Ortopedici Rizzoli, Bologna, Italy. [Boni V] START Madrid–Centro Integral Oncologico Clara Campal, Hospital Universitario Madrid Sanchinarro, Madrid, Spain. [Delord JP] Institut Claudius Regaud, Toulouse, France. [Awada A] Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
dc.identifier.pmid35486638
dc.identifier.wos000823311900001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record